DexCom, Inc.
Rank #114HypergrowthDXCM · Nasdaq · Healthcare
DexCom, Inc. (DXCM) — Rank #114 by gross profitability (GP/assets 0.43) · ROE 31.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001093557 · all metrics point-in-time as of the filing date.
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Show moreShow less
The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
The company was incorporated in 1999 and is headquartered in San Diego, California.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- dexcom.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$32.63B
P/E (annual)
41.4
P/S (annual)
7.0
P/B
12.4
P/OCF (annual)
22.6
Shareholder Yield
-483.5%
Employees
11,000
Industry
Medical Devices
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 3/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
14.3%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 483.5% — per-share value needs a total required return of 497.8% once share-count change is priced in.
vs. own 6-year median revenue growth: 56.8%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
9.6%
r = 10% (base)
14.3%
r = 12%
18.4%
Net debt / market cap: -8.2%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
Disclosure regression check
3 previously-disclosed line items are no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.43
Primary signal (Novy-Marx).
8th of 17 SIC 3841 peers
Return on equity
31.9%
Gross margin
60.1%
13th of 17 SIC 3841 peers
Revenue growth (YoY)
4566.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2011 | 2012 | 2013 | 2020 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
19.3%
Earnings CAGR (3Y)
34.8%
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.46
15th of 16 SIC 3841 peers (best = lowest)
Current ratio
1.73×
15th of 17 SIC 3841 peers
Quick ratio
1.66×
Net cash
$2.87B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$1.08B
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.29
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.4%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.